Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients
Clinical Infectious Diseases · 15.12.2023 · 77 (12) · 1723-1732
DOI: 10.1093/cid/ciad458 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.08.2023. Verfasst von Lora D Thomas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Hematopoietic Stem Cell Transplantation, Influenza, Human, Antibodies, Viral. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, NCATS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Adult hematopoietic cell transplant (HCT) recipients are at high risk for influenza-related morbidity and mortality and have suboptimal influenza vaccine immune responses compared to healthy adults, particularly within 2 years of transplant.
Methods
This phase II, double-blind, multicenter randomized controlled trial compared 2 doses of high-dose trivalent (HD-TIV) to 2 doses of standard-dose quadrivalent (SD-QIV) influenza vaccine administered 1 month apart in adults 3–23 months post-allogeneic HCT. Hemagglutinin antibody inhibition (HAI) titers were measured at baseline, 4 weeks following each vaccine dose, and approximately 7 months post-second vaccination. Injection-site and systemic reactions were assessed for 7 days post-vaccination. The primary immunogenicity comparison was geometric mean HAI titer (GMT) at visit 3 (4 weeks after the second dose); we used linear mixed models to estimate adjusted GMT ratios (aGMRs) comparing HD-TIV/SD-QIV for each antigen.
Results
We randomized 124 adults; 64 received SD-QIV and 60 received HD-TIV. Following the second vaccination, HD-TIV was associated with higher GMTs compared to SD-QIV for A/H3N2 (aGMR = 2.09; 95% confidence interval [CI]: [1.19, 3.68]) and B/Victoria (aGMR = 1.61; 95% CI: [1.00, 2.58]). The increase was not statistically significant for A/H1N1 (aGMR = 1.16; 95% CI: [0.67, 2.02]). There was a trend to more injection-site reactions for HD-TIV after the second vaccination compared to SD-QIV (50% vs 33%; adjusted odds ratio [aOR] = 4.53; 95% CI: [0.71, 28.9]), whereas systemic reactions were similar between groups with both injections.
Conclusions
Adult allogeneic HCT recipients who received 2 doses of HD-TIV produced higher HAI antibody responses for A/H3N2 and B/Victoria compared with 2 doses of SD-QIV, with comparable injection-site or systemic reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- 3Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Respiratory Disease Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
- Department of Medicine, University Hospital, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Medicine, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
ORCID-Profile: Lora D Thomas
Förderung
- NIH
- NCATS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Thomas, L. D., Batarseh, E., Hamdan, L., Haddadin, Z., Dulek, D., Kalams, S., Stewart, L. S., Stahl, A. L., Rahman, H., Amarin, J. Z., Hayek, H., Ison, M., Overton, E. T., Pergam, S. A., Spieker, A. J., Halasa, N. B., & Adult HCT Flu Study (2023). Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 77(12), 1723-1732. https://doi.org/10.1093/cid/ciad458
Vancouver
Thomas LD, Batarseh E, Hamdan L, Haddadin Z, Dulek D, Kalams S, et al. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases. 2023;77(12):1723-1732. doi:10.1093/cid/ciad458
BibTeX
@article{Thomas2023,
author = {Thomas, Lora D and Batarseh, Einas and Hamdan, Lubna and Haddadin, Zaid and Dulek, Daniel and Kalams, Spyros and Stewart, Laura S and Stahl, Anna L and Rahman, Herdi and Amarin, Justin Z and Hayek, Haya and Ison, Michael and Overton, Edgar T and Pergam, Steven A and Spieker, Andrew J and Halasa, Natasha B and Adult HCT Flu Study, Adult HCT Flu Study},
title = {Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {12},
pages = {1723--1732},
doi = {10.1093/cid/ciad458}
}
EUVIMED